← Back to Search

Tetrasodium EDTA for Catheter Complications

N/A

Recruiting

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 24 months

Awards & highlights

Study Summary

This trial found that tetrasodium EDTA was more effective than heparin at reducing thrombosis and infection in patients receiving parenteral nutrition through a central venous catheter.

Who is the study for?

This trial is for adults over 18 who are stable on home total parenteral nutrition (HTPN) without acute illnesses. It's not for those allergic to tetrasodium EDTA, unable to consent, with substance abuse issues, pregnant or breastfeeding women, or those with certain severe medical conditions.Check my eligibility

What is being tested?

The study tests a catheter lock solution called Tetrasodium EDTA in patients using HTPN. The goal is to see if it reduces complications like blood clots and infections better than other solutions such as heparin.See study design

What are the potential side effects?

Potential side effects may include reactions at the catheter site due to sensitivity to Tetrasodium EDTA ingredients. However, specific side effects aren't listed; they will be monitored throughout the trial.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Ease of use

Secondary outcome measures

Cost analysis

Time taken to use the catheter lock

Trial Design

1Treatment groups

Experimental Treatment

Group I: Tetrasodium EDTA cathether lock solutionExperimental Treatment1 Intervention

There is only one arm in this study where home parenteral nutrition patients who meet the inclusion criteria will receive tetrasodium EDTA catheter lock solution.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,474 Previous Clinical Trials

485,022 Total Patients Enrolled

Ennaliza SalazarStudy ChairTPN team

Media Library

Tetrasodium EDTA cathether lock solution Clinical Trial Eligibility Overview. Trial Name: NCT04067245 — N/A

Catheter Complications Research Study Groups: Tetrasodium EDTA cathether lock solution

Catheter Complications Clinical Trial 2023: Tetrasodium EDTA cathether lock solution Highlights & Side Effects. Trial Name: NCT04067245 — N/A

Tetrasodium EDTA cathether lock solution 2023 Treatment Timeline for Medical Study. Trial Name: NCT04067245 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there currently an opportunity to join this experiment?

"According to clinicaltrials.gov, this trial is actively seeking participants; it was initially listed on April 1st 2019 and last modified on November 1st 2022."

Answered by AI

Does this research endeavor have any age restrictions?

"This experiment is seeking participants aged 18 and over, up to the age of 100."

Answered by AI

How many participants are being recruited for this clinical experiment?

"Affirmative. Referring to the details published on clinicaltrials.gov, this clinical trial is seeking participants as of now and was initially posted on April 1st 2019. The current goal is to recruit 20 people from a single medical centre."

Answered by AI

Is it possible for me to enroll in this research endeavor?

"This clinical investigation is searching for 20 volunteers, aged 18 or above, suffering from catheter-associated complications. To qualify as a participant, they must have been in stable health with no co-morbidities for the last four weeks and be of either gender."

Answered by AI

Recent research and studies

Clinical Chemical Laboratory MedicineJournal

The Role of Ethylenediamine Tetraacetic Acid (EDTA) as in Vitro Anticoagulant for Diagnostic Purposes

Banfi, Giuseppe, Gian Luca Salvagno, and Giuseppe Lippi. 2007. “The Role of Ethylenediamine Tetraacetic Acid (EDTA) as in Vitro Anticoagulant for Diagnostic Purposes”. Clinical Chemical Laboratory Medicine. Walter de Gruyter GmbH. doi:10.1515/cclm.2007.110.

American Journal of Kidney DiseasesJournal

Citrate Versus Heparin Lock for Hemodialysis Catheters: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Zhao, Yuliang, Zheng Li, Ling Zhang, Jiqiao Yang, Yingying Yang, Yi Tang, and Ping Fu. 2014. “Citrate Versus Heparin Lock for Hemodialysis Catheters: A Systematic Review and Meta-analysis of Randomized Controlled Trials”. American Journal of Kidney Diseases. Elsevier BV. doi:10.1053/j.ajkd.2013.08.016.

Infection Control & Hospital EpidemiologyJournal

Tetrasodium EDTA as a Novel Central Venous Catheter Lock Solution Against Biofilm

Percival, Steven L., Peter Kite, Kerrie Eastwood, Ricardo Murga, Janice Carr, Matthew J. Arduino, and Rodney M. Donlan. 2005. “Tetrasodium EDTA as a Novel Central Venous Catheter Lock Solution Against Biofilm”. Infection Control & Hospital Epidemiology. Cambridge University Press (CUP). doi:10.1086/502577.

Clinical Infectious DiseasesJournal